BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...
Statin use linked to better survival but higher cardiac adverse events in advanced prostate cancer patients treated with ...
A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.
Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...
Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...
Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...
Wellbeing Whisper on MSN
Biden’s Aggressive Prostate Cancer: Treatments, Breakthroughs, and Outlook
A Gleason reading of 9 one of the most virulent forms of prostate cancer is now fueling ex-President Joe Biden’s treatment ...
Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback